Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > EY sees bolt-ons in the single to double digit billions now

<< Previous

Bullboard Posts

Next >>

Comment by jimsenioron Oct 07, 2022 11:57am

213 Views

Post# 35012396

RE:RE:RE:RE:RE:RE:RE:RE:RE:EY sees bolt-ons in the single to double digit billions now

to intho. I agree. This upcoming event should give us a few clues as to what the mindset is at ONC. I would feel more comfortable if Laeufle came back.

To digress it is tough to move big egos

Nevertheless a very interesting juncture for shareholders.

Best.

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023